SCHEMBL6157604

SCHEMBL6157604

N#Cc1cccc(NN(C(=O)Nc2ccc(N3CCCCC3=O)cc2)c2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 4/20 0.47
NPC1 O15118 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RAB9A P51151 3/20 0.45
TSHR P16473 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 2/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
PKM P14618 1/20 0.43
MCHR1 Q99705 1/20 0.41
HTT P42858 1/20 0.41
GAA P10253 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
GFER P55789 1/20 0.40
MAPT P10636 2/20 0.39
KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6156353 0.87 TP53 (0.40) SMN1; SMN2MEN1KMT2AALDH1A1TP53
SCHEMBL6156015 0.84 F10 (0.49) F10NPC1SMN1; SMN2RAB9ATSHR
SCHEMBL6329234 0.83 SMN1; SMN2 (0.42) F10NPC1SMN1; SMN2RAB9ATSHR
SCHEMBL6157482 0.83 F10 (0.68) F10NPC1SMN1; SMN2RAB9ATSHR
SCHEMBL6157579 0.83 F10 (0.48) F10NPC1SMN1; SMN2RAB9ATSHR
SCHEMBL6803971 0.76 ALDH1A1 (0.54) NPC1SMN1; SMN2RAB9ATSHRMEN1
SCHEMBL6156428 0.76 NPC1 (0.47) F10NPC1SMN1; SMN2RAB9ATSHR
SCHEMBL6331600 0.74 F10 (0.47) F10NPC1SMN1; SMN2RAB9ATSHR
SCHEMBL14408295 0.74 F10 (0.51) F10NPC1SMN1; SMN2RAB9ATSHR
SCHEMBL6159501 0.73 SMN1; SMN2 (0.50) F10NPC1SMN1; SMN2RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US claimed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP claimed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO claimed
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases SERPINC1, F11, F12 F10 6/4885NPC1 1451/4885SMN1; SMN2 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.